Effectiveness of Semaglutide for Weight Loss in Patients with Type 2 Diabetes and Obesity
Mechanism of Action and Efficacy
- Semaglutide is a GLP-1 receptor agonist that acts by stimulating insulin secretion, lowering glucagon secretion, delaying gastric emptying, and inhibiting food intake through actions on the hypothalamus 4
- The STEP trials demonstrated that in patients with obesity without diabetes, mean weight loss at 68 weeks was 14.9% with semaglutide 2.4 mg versus 2.4% with placebo 5, 6
- Weight loss outcomes are typically lower in individuals with T2DM (4-6.2%) compared to those without diabetes (6.1-17.4%) 7, 2
Dosing and Administration
- Semaglutide is FDA-approved for obesity management at 2.4 mg weekly subcutaneous injection (higher than doses used for T2DM alone) 4, 1
- Dose escalation is recommended to mitigate gastrointestinal side effects 1, 8
- Studies show that semaglutide must be used long-term, as cessation leads to significant weight regain (11.6% of lost weight regained after stopping treatment) 5, 6
Benefits Beyond Weight Loss
- Provides cardioprotective effects in select populations, with the SELECT study showing reduced risk of cardiovascular events in patients with obesity 5, 6
- Improves heart failure-related symptoms and physical limitations in patients with heart failure and preserved ejection fraction 6
Side Effects and Safety Considerations
- Most common adverse effects are gastrointestinal, including nausea, vomiting, diarrhea, and constipation 7, 2, 3
- Gradual dose titration helps mitigate gastrointestinal side effects 1, 8
- Pooled data from 8 RCTs showed a 38% higher risk of serious adverse events with semaglutide vs placebo 2, 3
- Contraindicated in patients with personal or family history of medullary thyroid cancer or multiple endocrine neoplasia syndrome type 2 2, 3
- Associated with increased risk of pancreatitis and gallbladder disease 1, 9
Practical Considerations for Use
- Semaglutide should be used in conjunction with lifestyle interventions (hypocaloric diet with 500-kcal daily deficit and 150 minutes of physical activity per week) 2, 3, 8
- Long-term use is necessary as weight regain occurs after discontinuation (6.9-11.6% of lost weight regained) 5, 6
- Patients should be monitored for gastrointestinal adverse effects, particularly during dose escalation 7, 1
Comparative Efficacy
- Semaglutide 2.4 mg produces greater weight loss than liraglutide 3.0 mg (8.0% weight loss at 56 weeks) 5, 6
- Newer dual GIP/GLP-1 receptor agonist tirzepatide shows even greater weight loss potential (15.0-20.9% at 72 weeks) compared to semaglutide 5, 6